<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912130</url>
  </required_header>
  <id_info>
    <org_study_id>LiverpoolHU</org_study_id>
    <nct_id>NCT02912130</nct_id>
  </id_info>
  <brief_title>Exercise and Nutrition Interventions in Age-related Sarcopenia</brief_title>
  <official_title>The Multidimensional Effects of Exercise and Nutritional Interventions on Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool Hope University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liverpool Hope University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will investigate the synergistic effects of Aerobic and Resistance type
      Exercise, in combination with Protein Supplementation, on; Body Composition, Musculoskeletal
      Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Musculoskeletal ageing is an inevitable process associated with profound morphological and
      functional changes that will ultimately transition an individual from independent, to
      dependable living, relying heavily on personal health care for survival. The United Kingdom
      (UK) population aged over 65 years is expected to rise from 8.8 to 11.3 million by 2025. As
      life expectancy increases due to advances in medical treatment, an age-related disease termed
      sarcopenia, has become more prevalent in the elderly. Sarcopenia, described as the loss of
      musculoskeletal mass, strength and/or physical functioning with age, manifests after the 6th
      decade and rapidly increases after the 8th decade, resulting in a deterioration of health
      status and quality of life. To manage the looming health and economic consequences of
      sarcopenia, suitable therapeutic strategies to manage the condition are warranted. Therefore,
      this randomised control trial (RCT) will investigate the effects of 16-weeks of exercise and
      nutritional interventions in inactive senior citizens (60 - 90 years old).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Composition: Lean Muscle/Fat Tissue 1) appendicular lean mass (kg) divided by height (meters-squared) and 2) appendicular lean mass divided by body mass index</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grip Strength: Hand Grip Dynanometer (kg)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait speed during timed 4-meter walk (m/s)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete five chair rises (m/s)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance assessment: 1) feet side to side, 2) semi-tandem, 3) full tandem, and 4) single leg. Scored as Yes or No.</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isometric Strength - Knee Flexion/Extension: Dynanometer (Nm/Kg)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Fatigue: Upper &amp; Lower limb: 25% of MVC during 60 seconds using Electromyography (EMG), measured in millivolts (mV)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Tolerance: Six Minute Walk Test (metres)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-metre Gait analysis during habitual walking speed using Electromyography (EMG)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-metre Gait analysis during habitual walking speed using Three-Dimensional Motion Capture - 1) Spatiotemporal, 2) Kinematics</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical: Glycated Haemoglobin (HBA1c) (%)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical: C-Reactive Protein (CRP) (mg/L)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical: Insulin-Like Growth Factor 1 (IGF-1) (ng/ml)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Pressure: Pulse Wave Velocity (m/s)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy Balance: Periodic Food Diary (Kcal)</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization Quality Of Life Assessment (WHOQOL): Each question is scored from 1-5 on a response scale</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form Health Survey (SF-12): Each question is scored between 1-6 on a response scale</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living (ADL): Each response is scored as either: 0 or 1</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE): Each correct response is scored as 1 point</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Status: Mini-Nutritional Assessment (MNA) - Classified as (Low, Moderate, High risk)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
Resistance Exercise i.e. 60 minutes per week of progressive resistance training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise+Nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Supplementation</intervention_name>
    <description>1.2-1.5g/kg/body weight per day</description>
    <arm_group_label>Exercise+Nutrition</arm_group_label>
    <arm_group_label>Nutrition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aerobic Exercise</intervention_name>
    <description>30-60 minutes per week of moderate intensity exercise</description>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_label>Exercise+Nutrition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resistance Exercise</intervention_name>
    <description>60 minutes per week of progressive resistance training</description>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_label>Exercise+Nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female participants

          -  60 - 90 years of age

          -  Resident in North West, England, UK

          -  BMI 18.5-30 kg/m

          -  Can speak and understand English

          -  Willing to consent and follow the study procedures

        Exclusion Criteria:

          -  Recent (i.e. past 3 months) or concurrent participation in any clinical trial or
             dietary and/or exercise intervention program

          -  Self-reported lactose intolerance

          -  Uncontrolled diabetes (HbA1C &gt;10)

          -  Uncontrolled Hypertension (160/100) and uncontrolled hypotension (&lt;100 systolic)

          -  Treatment with Beta Blockers, Calcium Channel Blockers, Digitalis, Bronchodilator,

          -  Diuretics, Vasodilators

          -  Current hormone therapy such as insulin, testosterone or hormone replacement therapy

          -  History of falls/osteoporosis

          -  Major psychological/mental illness

          -  Medical conditions that precluded safe participation in an exercise program

          -  Other major systemic diseases: Liver and kidney diseases, Advanced gastrointestinal
             disorders, Cardiovascular Diseases, Advanced chronic obstructive pulmonary disease,
             Advanced Rheumatoid Arthritis, Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Omid Alizadehkhaiyat, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Hope University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Omid Alizadehkhaiyat, MD, PhD</last_name>
    <phone>(+44) 0151 291 3262</phone>
    <email>alizado@hope.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Farzad Amirabdhollahian, PhD</last_name>
    <phone>(+44) 0151 291 3799</phone>
    <email>amirabf@hope.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liverpool Hope University</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L16 9JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Kirk, BSc, MSc</last_name>
      <phone>(+44) 0151 291 3815</phone>
      <email>kirkb@hope.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kate Mooney, BSc, MSc</last_name>
      <phone>(+44) 0151 291 3815</phone>
      <email>mooneyk1@hope.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ben Kirk, BSc, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kate Mooney, BSc, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omid Alizadehkhaiyat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farzad Amirabdollahian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://twitter.com/StudyAgeing</url>
    <description>Recruitment Links: Social Media</description>
  </link>
  <link>
    <url>https://www.facebook.com/HopeHealthyAgeing/</url>
    <description>Recruitment Links: Social Media</description>
  </link>
  <reference>
    <citation>Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.</citation>
    <PMID>20392703</PMID>
  </reference>
  <reference>
    <citation>Witard OC, Wardle SL, Macnaughton LS, Hodgson AB, Tipton KD. Protein Considerations for Optimising Skeletal Muscle Mass in Healthy Young and Older Adults. Nutrients. 2016 Mar 23;8(4):181. doi: 10.3390/nu8040181. Review.</citation>
    <PMID>27023595</PMID>
  </reference>
  <reference>
    <citation>Lourenço RA, Pérez-Zepeda M, Gutiérrez-Robledo L, García-García FJ, Rodríguez Mañas L. Performance of the European Working Group on Sarcopenia in Older People algorithm in screening older adults for muscle mass assessment. Age Ageing. 2015 Mar;44(2):334-8. doi: 10.1093/ageing/afu192. Epub 2014 Dec 23.</citation>
    <PMID>25539836</PMID>
  </reference>
  <reference>
    <citation>Yu SC, Khow KS, Jadczak AD, Visvanathan R. Clinical Screening Tools for Sarcopenia and Its Management. Curr Gerontol Geriatr Res. 2016;2016:5978523. doi: 10.1155/2016/5978523. Epub 2016 Feb 4. Review.</citation>
    <PMID>26966433</PMID>
  </reference>
  <reference>
    <citation>Churchward-Venne TA, Holwerda AM, Phillips SM, van Loon LJ. What is the Optimal Amount of Protein to Support Post-Exercise Skeletal Muscle Reconditioning in the Older Adult? Sports Med. 2016 Sep;46(9):1205-12. doi: 10.1007/s40279-016-0504-2. Review.</citation>
    <PMID>26894275</PMID>
  </reference>
  <reference>
    <citation>Kraschnewski JL, Sciamanna CN, Poger JM, Rovniak LS, Lehman EB, Cooper AB, Ballentine NH, Ciccolo JT. Is strength training associated with mortality benefits? A 15year cohort study of US older adults. Prev Med. 2016 Jun;87:121-127. doi: 10.1016/j.ypmed.2016.02.038. Epub 2016 Feb 24.</citation>
    <PMID>26921660</PMID>
  </reference>
  <reference>
    <citation>Witard OC, McGlory C, Hamilton DL, Phillips SM. Growing older with health and vitality: a nexus of physical activity, exercise and nutrition. Biogerontology. 2016 Jun;17(3):529-46. doi: 10.1007/s10522-016-9637-9. Epub 2016 Feb 15. Review.</citation>
    <PMID>26878863</PMID>
  </reference>
  <reference>
    <citation>Chang SF, Lin PL. Systematic Literature Review and Meta-Analysis of the Association of Sarcopenia With Mortality. Worldviews Evid Based Nurs. 2016 Apr;13(2):153-62. doi: 10.1111/wvn.12147. Epub 2016 Feb 4. Review.</citation>
    <PMID>26844538</PMID>
  </reference>
  <reference>
    <citation>Csapo R, Alegre LM. Effects of resistance training with moderate vs heavy loads on muscle mass and strength in the elderly: A meta-analysis. Scand J Med Sci Sports. 2016 Sep;26(9):995-1006. doi: 10.1111/sms.12536. Epub 2015 Aug 24. Review.</citation>
    <PMID>26302881</PMID>
  </reference>
  <reference>
    <citation>Xu ZR, Tan ZJ, Zhang Q, Gui QF, Yang YM. Clinical effectiveness of protein and amino acid supplementation on building muscle mass in elderly people: a meta-analysis. PLoS One. 2014 Sep 30;9(9):e109141. doi: 10.1371/journal.pone.0109141. eCollection 2014.</citation>
    <PMID>25268791</PMID>
  </reference>
  <reference>
    <citation>Komar B, Schwingshackl L, Hoffmann G. Effects of leucine-rich protein supplements on anthropometric parameter and muscle strength in the elderly: a systematic review and meta-analysis. J Nutr Health Aging. 2015 Apr;19(4):437-46. doi: 10.1007/s12603-014-0559-4. Review.</citation>
    <PMID>25809808</PMID>
  </reference>
  <reference>
    <citation>Ko SU, Hausdorff JM, Ferrucci L. Age-associated differences in the gait pattern changes of older adults during fast-speed and fatigue conditions: results from the Baltimore longitudinal study of ageing. Age Ageing. 2010 Nov;39(6):688-94. doi: 10.1093/ageing/afq113. Epub 2010 Sep 10.</citation>
    <PMID>20833863</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liverpool Hope University</investigator_affiliation>
    <investigator_full_name>Omid Alizadehkhaiyat</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Sarcopenia</keyword>
  <keyword>Healthy Ageing</keyword>
  <keyword>Elderly</keyword>
  <keyword>Muscular Hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

